Baudax Bio

Baudax Bio is a revenue-generating specialty pharmaceutical company founded in 2015 and based in the United States. The company's focus is on developing and commercializing innovative products for acute care settings. It currently promotes its lead product, ANJESO™, which is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Baudax Bio's pipeline includes multiple non-opioid therapeutics in clinical development for pain conditions, as well as other early-stage product candidates, such as novel neuromuscular blocker agents (NMBs) and a proprietary intranasal formulation of dexmedetomidine.

The company is actively pursuing opportunities to create value for patients and shareholders through its robust pipeline of product candidates. Moreover, Baudax Bio is evaluating acquisition and licensing opportunities that align with its core acute care focus, indicating a proactive approach to growth and expansion in the biotechnology and pharmaceutical industries.

Furthermore, it secured a $1.90M Post-IPO Equity investment on 17 August 2023, a testament to investor confidence in the company's prospects. The specifics of the investors behind this investment are not disclosed. With its promising product portfolio and strategic investment, Baudax Bio aims to play a significant role in advancing acute care therapeutics and solidifying its position in the market.